RYBREVANT FASPRO™ Receives FDA Approval for First-Line EGFR-Mutated NSCLC
December 26, 2025
Brand Name :
Synonyms :
Class :
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the adverse/toxic effect of bisphosphonate derivatives
may enhance the risk of adverse effect of bisphosphonate derivatives
may enhance the risk of adverse effect of bisphosphonate derivatives
may enhance the risk of adverse effect of bisphosphonate derivatives
may enhance the risk of adverse effect of bisphosphonate derivatives
may increase the risk of adverse effects